Treatment Shortening of MDR-TB Using Existing and New Drugs

PHASE2CompletedINTERVENTIONAL
Enrollment

214

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions
Tuberculosis, Multidrug-Resistant
Interventions
DRUG

Linezolid

DRUG

Delamanid

DRUG

Levofloxacin

DRUG

Pyrazinamide

DRUG

Locally-used WHO-approved MDR-TB regimen in Korea

Trial Locations (1)

110-744

Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine, Seoul

All Listed Sponsors
collaborator

Asan Medical Center

OTHER

collaborator

Dankook University

OTHER

collaborator

International Tuberculosis Research Center

OTHER

collaborator

Pusan National University Yangsan Hospital

OTHER

collaborator

Pusan National University Hospital

OTHER

collaborator

Samsung Medical Center

OTHER

collaborator

Severance Hospital

OTHER

collaborator

SMG-SNU Boramae Medical Center

OTHER

collaborator

Incheon St.Mary's Hospital

OTHER

collaborator

Ulsan University Hospital

OTHER

collaborator

Korean Institute of Tuberculosis

OTHER

collaborator

National Medical Center, Seoul

OTHER

collaborator

Korean Center for Disease Control and Prevention

OTHER_GOV

collaborator

Korea University Ansan Hospital

OTHER

lead

Seoul National University Hospital

OTHER

NCT02619994 - Treatment Shortening of MDR-TB Using Existing and New Drugs | Biotech Hunter | Biotech Hunter